Abstract
In the 70-80th of last century, it has been shown that the antidiabetic biguanide drugs phenformin (PF) and buformin (BF) can exert an inhibitory action on carcinogenesis in animal models and increase from 5 to 10-years survival of cancer patients. Since 2005, after first evidence publication of the capacity of metformin (MF), another biguanide, to prevent development of malignant tumors in individuals with type 2 diabetes (T2D) and suppress tumorigenesis in mice, the burst of studies started in this field focused on breast, pancreas, prostatic, endometrial and some other cancers. Colorectal cancer (CRC) is the most prevalent among digestive system cancers. In this mini-review are presented the available data on the capacity of antidiabetic biguanide drugs to prevent colorectal carcinogenesis and growth in vitro and in vivo in experimental models and clinical observations.
Keywords: Colorectal cancer, metformin, prevention, treatment.
Current Drug Targets
Title:Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data
Volume: 17 Issue: 4
Author(s): Vladimir N. Anisimov
Affiliation:
Keywords: Colorectal cancer, metformin, prevention, treatment.
Abstract: In the 70-80th of last century, it has been shown that the antidiabetic biguanide drugs phenformin (PF) and buformin (BF) can exert an inhibitory action on carcinogenesis in animal models and increase from 5 to 10-years survival of cancer patients. Since 2005, after first evidence publication of the capacity of metformin (MF), another biguanide, to prevent development of malignant tumors in individuals with type 2 diabetes (T2D) and suppress tumorigenesis in mice, the burst of studies started in this field focused on breast, pancreas, prostatic, endometrial and some other cancers. Colorectal cancer (CRC) is the most prevalent among digestive system cancers. In this mini-review are presented the available data on the capacity of antidiabetic biguanide drugs to prevent colorectal carcinogenesis and growth in vitro and in vivo in experimental models and clinical observations.
Export Options
About this article
Cite this article as:
Anisimov N. Vladimir, Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data, Current Drug Targets 2016; 17 (4) . https://dx.doi.org/10.2174/1389450116666150309113305
DOI https://dx.doi.org/10.2174/1389450116666150309113305 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine
Current Drug Targets L9 Orthogonal Design Assisted Formulation and Evaluation of Chitosanbased Buccoadhesive Films of Miconazole Nitrate
Current Drug Delivery Esophagogastric Cancer: Integration of Targeted Therapies into Systemic Chemotherapy
Current Cancer Drug Targets From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry PET Tracers Based on Zirconium-89
Current Radiopharmaceuticals The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA Withdrawal Notice: Role of MicroRNAs (224 and 96) as Novel Biomarkers for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Chemotherapy in Addition to Preoperative Radiotherapy in Locally Advanced Rectal Cancer – A Systematic Overview
Reviews on Recent Clinical Trials Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment
Current Medicinal Chemistry Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art
Clinical Cancer Drugs Editorial: Role of Cancer Stem Cells in Common Gastrointestinal Cancers: From Pathogenesis to Therapeutic Targets
Current Stem Cell Research & Therapy The Role of Folate-supplementation in Depression: A Narrative Review
Current Psychopharmacology An Overview of Compounds Derived from the Shikimate and Phenylpropanoid Pathways and Their Medicinal Importance
Mini-Reviews in Medicinal Chemistry CYLD-Mediated Signaling and Diseases
Current Drug Targets Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Approaches to Gastrointestinal Cytoprotection: From Isolated Cells, Via Animal Experiments to Healthy Human Subjects and Patients with Different Gastrointestinal Disorders
Current Pharmaceutical Design Heterologous Expression and Characterization of Flavinadenine Dinucleotide Synthetase from <i>Candida famata</i> for Flavin Adenine Dinucleotide Production
Protein & Peptide Letters The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design